Updated:
BIOXYTRAN, INC
BIOXYTRAN, INC is a other; the Altss profile covers its classification, headquarters, registration, AUM band, and key contacts for private-markets fundraising...
BIOXYTRAN, INC
Developing new drugs under FDA regulation for hypoxia brain and heart ischemia and viral infection like coronavirus and influenza.
General information
Firm type
other
Principals
David Platt
Chief Executive Officer
Michael Sheikh
Chief Financial Officer
Sector focus
Frequently asked questions
What is Bioxytran's lead drug candidate?
The lead asset is BXT-25, a brain-tropic oxygen carrier designed to treat acute ischemic stroke by transporting oxygen across the blood-brain barrier. The firm has also explored additional applications for its carbohydrate-based platform in wound care and antiviral indications.
How is Bioxytran funded as a clinical-stage company?
Bioxytran does not operate with a traditional venture capital backing. It has remained publicly traded on OTC markets and raises capital through equity financings and convertible instruments, making its financial structure atypical for a pre-revenue biotech.
Who controls decision-making at Bioxytran?
David Platt serves as CEO and appears to direct the scientific strategy, while Michael Sheikh acts as CFO, overseeing the financial architecture. Public filings list them as the primary officers, suggesting concentrated operational control.
Does Bioxytran have any partnership with major pharmaceutical companies?
There is no public record of a partnership with a major pharmaceutical firm. Bioxytran's disclosed collaborations have primarily involved contract research organizations and academic institutions for its clinical and preclinical work.
Is Bioxytran structured as a venture-backed private company?
No. Bioxytran is publicly traded on OTC markets, a structural anomaly for a clinical-stage biotech. This allows retail investors to participate directly, bypassing the venture capital gatekeepers that typically fund early drug development.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: